Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells.

OBJECTIVE: Trastuzumab has been used for the treatment of HER2-positive breast cancer (BC). However, a subset of BC patients exhibited resistance to trastuzumab therapy. Thus, clarifying the molecular mechanism of trastuzumab treatment will be beneficial to improve the treatment of HER2-positive BC...

Full description

Bibliographic Details
Main Authors: Takehiro Ichikawa, Fumiaki Sato, Kazuya Terasawa, Soken Tsuchiya, Masakazu Toi, Gozoh Tsujimoto, Kazuharu Shimizu
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3288043?pdf=render